Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

WESTLAKE VILLAGE, Calif., March 16, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and...

XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection XRx-101 – a triple action approach to suppressing COVID-19 Injury

CALGARY, Alberta, March 16, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late...
SEARCH FOR STUDIES